Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Dec 2;11:10135–10143. doi: 10.2147/CMAR.S222620

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 Jiang et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

CSNK2A1 modulates the PI3K-Akt-mTOR signaling pathway. (A) The Western blot results show that the levels of p-Akt S473/T308 and p-mTOR were increased in CSNK2A1-overexpressing cells and decreased in CSNK2A1-knockdown cells. (B) The levels of p-Akt S473/T308 and p-mTOR were decreased after treatment with a PI3K inhibitor (ly294002) in the CSNK2A1-overexpressing GC cell line. (C) The migratory and invasive abilities were markedly reduced after PI3K inhibitor ly294002 treatment in the CSNK2A1-overexpressing GC cell line. (D) A CCK-8 assay was used to detect the viability of cells treated with empty vector, CSNK2A1 and CSNK2A1+ ly294002. (*P<0.05; ** P<0.01; ***P<0.001).